VEGF-targeted therapy: therapeutic potential and recent advances

LS Rosen - The oncologist, 2005 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Compare and contrast the mechanism of action for angiogenesis inhibitors currently being …

VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future

PS Sharma, R Sharma, T Tyagi - Current cancer drug targets, 2011 - ingentaconnect.com
Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a central
role in the process of tumor growth and metastasis. The proliferation of endothelium and …

VEGF signaling in cancer treatment

D Sia, C Alsinet, P Newell… - Current pharmaceutical …, 2014 - ingentaconnect.com
Induction of angiogenesis represents one of the major hallmarks of cancer. The growth of
new vessels is crucial to provide malignant cells with an adequate supply of oxygen and …

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy

A Veeravagu, AR Hsu, W Cai, LC Hou… - Recent patents on …, 2007 - ingentaconnect.com
New blood vessel formation (angiogenesis) is fundamental to the process of tumor growth,
invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) …

Vascular endothelial growth factor-dependent and-independent regulation of angiogenesis

M Shibuya - BMB reports, 2008 - koreascience.kr
Angiogenesis, the formation of blood vessels, is essential for preparing a closed circulatory
system in the body, and for supplying oxygen and nutrition to tissues. Major diseases such …

Inhibitors of the vascular endothelial growth factor receptor

LS Rosen - Hematology/Oncology Clinics, 2002 - hemonc.theclinics.com
In 1966, Folkman et al first theorized that tumor growth beyond 1 to 2 mm3 depends on a
process called angiogenesis—the development of new tumorassociated blood vessels that …

Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.

LM Ellis, L Rosen, MS Gordon - Clinical advances in hematology & …, 2006 - europepmc.org
Several new agents that target the vascular endothelial growth factor (VEGF) pathway and
inhibit angiogenesis are emerging as promising therapies in multiple cancer types …

Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials

C Zhang, C Tan, H Ding, T Xin… - Current pharmaceutical …, 2012 - ingentaconnect.com
Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key
roles in tumor growth and metastasis. Selective inhibition of VEGFR kinase has been …

Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers

LS Rosen - Cancer control, 2002 - journals.sagepub.com
Angiogenesis is required for tumor growth and metastasis and, therefore, represents an
exciting target for cancer treatment. Angiogenesis is a complex process that is tightly …

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

DJ Hicklin, LM Ellis - Journal of clinical oncology, 2005 - ascopubs.org
New blood vessel formation (angiogenesis) is a fundamental event in the process of tumor
growth and metastatic dissemination. Hence, the molecular basis of tumor angiogenesis has …